Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.Aygun, B. Lane, A. Smart, L. R. Santos, B. Tshilolo, L. Williams, T. N. Olupot-Olupot, P. Stuber, S. E. Tomlinson, G. Latham, T. Ware, R. E. Reach Investigators
Lancet Haematol, (2024). 11:e425-e435